P-059 Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)

Documenti analoghi

• Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study
  di: Satake, Hironaga, et al.
  Pubblicazione: (2018)
• A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
  di: Satake, Hironaga, et al.
  Pubblicazione: (2018)
• Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
  di: Satake, Hironaga, et al.
  Pubblicazione: (2018)
• Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
  di: Masuishi, Toshiki, et al.
  Pubblicazione: (2020)
• P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study
  di: Kotaka, M., et al.
  Pubblicazione: (2016)